Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Jacobs & Co. CA

Jacobs & Co. CA lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 2.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 27,262 shares of the biopharmaceutical company’s stock after acquiring an additional 725 shares during the period. Jacobs & Co. CA’s holdings in Gilead Sciences were worth $1,997,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the company. Rathbones Group PLC acquired a new position in shares of Gilead Sciences during the third quarter valued at approximately $302,000. LPL Financial LLC lifted its holdings in shares of Gilead Sciences by 5.9% in the third quarter. LPL Financial LLC now owns 855,585 shares of the biopharmaceutical company’s stock valued at $64,118,000 after buying an additional 47,547 shares during the period. Mariner LLC boosted its stake in Gilead Sciences by 0.7% during the third quarter. Mariner LLC now owns 171,829 shares of the biopharmaceutical company’s stock valued at $12,877,000 after buying an additional 1,191 shares in the last quarter. Cary Street Partners Investment Advisory LLC grew its holdings in Gilead Sciences by 75.3% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 4,289 shares of the biopharmaceutical company’s stock worth $321,000 after acquiring an additional 1,842 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Gilead Sciences by 70.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 47,084 shares of the biopharmaceutical company’s stock worth $3,528,000 after acquiring an additional 19,436 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Down 0.3 %

GILD traded down $0.23 during midday trading on Tuesday, hitting $70.50. 1,729,685 shares of the company’s stock traded hands, compared to its average volume of 7,592,006. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The company has a market cap of $87.83 billion, a PE ratio of 196.47, a price-to-earnings-growth ratio of 1.42 and a beta of 0.20. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The stock’s fifty day simple moving average is $65.80 and its 200-day simple moving average is $72.84.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. During the same period in the prior year, the business posted $1.37 earnings per share. The business’s quarterly revenue was up 5.3% on a year-over-year basis. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 3.76 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.37%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. UBS Group lowered their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 27th. Maxim Group cut their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, May 1st. Oppenheimer reiterated an “outperform” rating and issued a $105.00 price target on shares of Gilead Sciences in a research report on Friday, April 19th. Finally, Morgan Stanley cut their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. Twelve equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $83.47.

Check Out Our Latest Research Report on Gilead Sciences

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.